State Key Laboratory for Liver Research and Department of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
Hepatology. 2018 Jun;67(6):2254-2270. doi: 10.1002/hep.29683. Epub 2018 Apr 19.
Epigenetic alterations have contributed greatly to human carcinogenesis. Conventional epigenetic studies have predominantly focused on DNA methylation, histone modifications, and chromatin remodeling. Recently, diverse and reversible chemical modifications of RNAs have emerged as a new layer of epigenetic regulation. N6-methyladenosine (m6A) is the most abundant chemical modification of eukaryotic messenger RNA (mRNA) and is important for the regulation of mRNA stability, splicing, and translation. Using transcriptome sequencing, we discovered that methyltransferase-like 3 (METTL3), a major RNA N6-adenosine methyltransferase, was significantly up-regulated in human hepatocellular carcinoma (HCC) and multiple solid tumors. Clinically, overexpression of METTL3 is associated with poor prognosis of patients with HCC. Functionally, we proved that knockdown of METTL3 drastically reduced HCC cell proliferation, migration, and colony formation in vitro. Knockout of METTL3 remarkably suppressed HCC tumorigenicity and lung metastasis in vivo. On the other hand, using the CRISPR/dCas9-VP64 activation system, we demonstrated that overexpression of METTL3 significantly promoted HCC growth both in vitro and in vivo. Through transcriptome sequencing, m6A sequencing, and m6A methylated RNA immuno-precipitation quantitative reverse-transcription polymerase chain reaction, we identified suppressor of cytokine signaling 2 (SOCS2) as a target of METTL3-mediated m6A modification. Knockdown of METTL3 substantially abolished SOCS2 mRNA m6A modification and augmented SOCS2 mRNA expression. We also showed that m6A-mediated SOCS2 mRNA degradation relied on the m6A reader protein YTHDF2-dependent pathway.
METTL3 is frequently up-regulated in human HCC and contributes to HCC progression. METTL3 represses SOCS2 expression in HCC through an m6A-YTHDF2-dependent mechanism. Our findings suggest an important mechanism of epigenetic alteration in liver carcinogenesis. (Hepatology 2018;67:2254-2270).
表观遗传改变极大地促进了人类的癌症发生。传统的表观遗传学研究主要集中在 DNA 甲基化、组蛋白修饰和染色质重塑上。最近,RNA 的各种可逆化学修饰作为新的表观遗传调控层出现。N6-甲基腺苷(m6A)是真核信使 RNA(mRNA)最丰富的化学修饰,对 mRNA 稳定性、剪接和翻译的调节很重要。通过转录组测序,我们发现甲基转移酶样 3(METTL3),一种主要的 RNA N6-腺苷甲基转移酶,在人类肝癌(HCC)和多种实体瘤中显著上调。临床上,METTL3 的过表达与 HCC 患者的预后不良相关。功能上,我们证明 METTL3 的敲低可显著降低 HCC 细胞的体外增殖、迁移和集落形成。METTL3 的敲除显著抑制体内 HCC 肿瘤发生和肺转移。另一方面,我们使用 CRISPR/dCas9-VP64 激活系统,证明 METTL3 的过表达在体外和体内均显著促进 HCC 的生长。通过转录组测序、m6A 测序和 m6A 修饰 RNA 免疫沉淀定量逆转录聚合酶链反应,我们确定了细胞因子信号转导抑制因子 2(SOCS2)为 METTL3 介导的 m6A 修饰的靶标。METTL3 的敲低显著消除了 SOCS2 mRNA 的 m6A 修饰并增加了 SOCS2 mRNA 的表达。我们还表明,m6A 介导的 SOCS2 mRNA 降解依赖于 m6A 读取蛋白 YTHDF2 依赖性途径。
METTL3 在人类 HCC 中频繁上调,并促进 HCC 进展。METTL3 通过 m6A-YTHDF2 依赖机制抑制 HCC 中的 SOCS2 表达。我们的研究结果表明,在肝致癌作用中存在重要的表观遗传改变机制。(《肝脏病学》2018;67:2254-2270)。